Full-Time

Encryption Agility Service Lead

Updated on 9/11/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's, PhD, Associate's

Category
Cybersecurity (1)
Required Skills
PowerShell
Bash
Fortinet
Python
ServiceNow
Data Engineering
AWS
Cryptography
HashiCorp Vault
REST APIs
DevOps

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A doctorate degree with 2 years of experience, a master's degree with 8 to 10 years of experience, a bachelor's degree with 10 to 14 years of experience, or a diploma with 14 to 18 years of experience in Information Security, Cybersecurity, Cryptography, Security Architecture, Computer Science, Information Technology, Engineering, or a related field is required.
  • CISSP certification is required.
  • Expert knowledge of enterprise cryptography, including Public Key Infrastructure, X.509 certificates, Transport Layer Security, cipher suites, Key Management Services, Hardware Security Modules, secrets management, key lifecycle, encryption at rest and in transit, and cloud key services is required.
  • Proven experience leading global information security, security architecture, or cryptography programs, including roadmap ownership, team management, resource planning, metrics, reporting, and executive stakeholder management is required.
  • Practical knowledge of post-quantum cryptography, crypto agility, National Institute of Standards and Technology-approved algorithms and standards, hybrid/post-quantum cryptography transition patterns, cryptographic discovery, and Cryptographic Bill of Materials-driven remediation is required.
  • Ability to translate security policy into enforceable controls across Continuous Integration/Continuous Delivery, cloud platforms, identity, Public Key Infrastructure and certificates, infrastructure, applications, third-party governance, and risk management is required.
  • Excellent people leadership, coaching, mentoring, and performance management skills are required.
  • Strong executive presence and ability to translate complex cryptographic risk into clear business impact and action plans is required.
  • Strong verbal and written communication skills for technical, business, legal, procurement, compliance, and executive audiences are required.
  • Ability to influence without direct authority across global security, DTI, DIAS, procurement, legal, compliance, Operational Technology, infrastructure, and application teams is required.
  • Ability to manage multiple priorities, competing stakeholder needs, and long-running transformation roadmaps successfully is required.
  • Ability to balance hands-on technical analysis with service ownership, people leadership, and enterprise change management is required.
Responsibilities
  • Establish, operate, and continuously improve the enterprise Encryption Agility Team and Service, including its charter, governance model, operating cadence, intake process, RACI model, roadmap, KPIs, KRIs, executive reporting, and service improvement plan.
  • Lead, coach, mentor, and manage Encryption Agility Team members, including full-time employees, external workers, cryptographic engineers, security architecture analysts, product ownership support, and part-time contributors from partner teams.
  • Partner with the Principal Architect to translate enterprise Post-Quantum Cryptography strategy into standards, specifications, reference architectures, implementation patterns, engineering guidance, remediation backlogs, and production-ready cryptographic design decisions.
  • Own the enterprise cryptographic standards and specifications roadmap, including approved algorithms, key sizes, protocols, Transport Layer Security and cipher policies, certificate requirements, Key Management Services and secrets requirements, exception criteria, Rivest-Shamir-Adleman and Elliptic Curve Cryptography sunset planning, and annual standards refresh.
  • Lead delivery across the full post-quantum cryptography lifecycle, including assessment wrap-up, discovery tooling selection, iterative discovery, vendor and third-party outreach, architecture, testing, production rollout, automation, monitoring, and steady-state service operations.
  • Build, govern, and mature the Amgen Cryptographic Bill of Materials, including required fields, asset ownership, quantum-vulnerability status, remediation status, data-quality controls, reporting requirements, and inventory and risk-data integration.
  • Direct enterprise cryptographic discovery across source code, binaries, cloud key services, endpoints, file systems, network traffic, Public Key Infrastructure and certificates, Key Management Services and secrets, vendor attestations, and subject-matter-expert interviews.
  • Apply the approved post-quantum cryptography risk-prioritization approach to sequence discovery and remediation for business-critical applications, sensitive data flows, identity services, third-party dependencies, legacy platforms, Key Computerized Systems, and validated Good x Practice systems.
  • Coordinate certificate, Public Key Infrastructure, cloud, infrastructure, and platform operations covering certificate visibility, Certificate Lifecycle Manager evaluation, rotation policy, deployment automation, post-quantum Public Key Infrastructure readiness, hybrid certificate testing, Certificate Authority roadmap, Key Management Services, Hardware Security Modules, secrets management, key rotation, and key retirement.
  • Partner with Application Security, Secure Software Development Lifecycle, DevOps, Artificial Intelligence Security, Enterprise Architecture, and engineering teams to publish approved cryptographic libraries, reusable patterns, Continuous Integration/Continuous Delivery controls, scanning rules, secure code examples, and remediation playbooks.
  • Coordinate with Risk and Compliance, Legal, Procurement, Third-Party Risk Management, and vendor management to implement post-quantum cryptography questionnaires, Cryptographic Bill of Materials requests, contract language, supplier roadmap tracking, risk acceptance, and executive escalation.
  • Provide senior technical escalation and hands-on leadership for cryptographic standards exceptions, scan findings, false-positive triage, certificate outages, key and secret configuration issues, tool integration blockers, design tradeoffs, Steal-Now-Decrypt-Later exposure, identity and certificate risks, outdated Transport Layer Security and cipher configurations, legacy cryptography, untracked keys, manual certificate processes, Operational Technology scope, developer enablement, and changes in applicable cryptography standards and guidance.
Desired Qualifications
  • CISM, CISA, or CRISC certification is preferred.
  • CCSP or a cloud security certification such as AWS Certified Security - Specialty or Azure Security Engineer is preferred.
  • TOGAF or SABSA certification is preferred.
  • ITIL, SAFe, product management, or program management certification is preferred.
  • Relevant Public Key Infrastructure, Key Management Services, Hardware Security Module, cryptographic discovery, or certificate lifecycle management vendor certifications are preferred.
  • Hands-on experience with ServiceNow CMDB/GRC, Guard, Wiz, Qualys, Fortinet, Netskope, CrowdStrike, GitLab, Veracode, AWS Key Management Services, AWS Certificate Manager, AWS Secrets Manager, Microsoft Public Key Infrastructure, Sectigo, HashiCorp Vault, Hardware Security Modules, Certificate Lifecycle Manager, and SIEM/data lake integrations is preferred.
  • Experience designing or operating Cryptographic Bill of Materials or Software Bill of Materials data models using CycloneDX 1.6 or later, APIs, CSV/JSON exports, dashboards, and data-quality controls is preferred.
  • Experience coordinating Public Key Infrastructure and certificate operations with Digital Identity Access Services or equivalent infrastructure and certificate service owners is preferred.
  • Experience in validated/Good x Practice, manufacturing, Operational Technology, Key Computerized Systems, or highly regulated environments, including change control and revalidation impacts, is preferred.
  • Experience with vendor and third-party risk management, supplier cryptographic questionnaires, contract requirements, and vendor roadmap tracking is preferred.
  • Scripting and automation experience with Python, PowerShell, Bash, REST APIs, or data pipeline tooling is preferred.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $38.2 billion-$39.4 billion.
  • Repatha sales jumped 37% to $953 million in Q2 2026, with U.S. prescriptions up 50%.
  • MariTide advanced through multiple Phase 3 studies in 2026, supporting a 2027 obesity catalyst.

What critics are saying

  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy cash cow.
  • FDA proposed withdrawing Tavneos in April 2026, signaling regulatory risk from integrity and efficacy issues.
  • Olpasiran now faces Novartis pelacarsen failure scrutiny; a negative 2028 OCEAN(a) readout would crush Lp(a) upside.

What makes Amgen unique

  • Repatha, Evenity, and Uplizna diversify Amgen beyond one blockbuster, per August 2026 sales.
  • MariTide targets quarterly or eight-week dosing, unlike Lilly and Novo Nordisk weekly injections.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-enabled drug discovery globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.

Yahoo Finance
Sep 7th, 2026
Amgen's $437 olpasiran bet faces higher bar after Novartis Lp(a) drug fails Phase 3 trial

Amgen faces heightened scrutiny for its experimental heart drug olpasiran after rival Novartis's pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial, despite successfully lowering lipoprotein(a) levels. The setback demonstrates that improving laboratory biomarkers may not translate to better patient outcomes. Amgen's OCEAN(a) outcomes study has enrolled 7,297 participants and is tracking heart-related deaths and procedures over roughly five years. While olpasiran uses a different design and may target different patients, pelacarsen's failure removes assumptions about the commercial value of lowering Lp(a). Amgen's shares traded at $437.23, sitting 19.54% above its estimated fair value of $365.76. The company reported $10.1 billion in second-quarter revenue and $3.5 billion in free cash flow.

Yahoo Finance
Sep 1st, 2026
Amgen's Repatha hits $953M in Q2 sales, up 37% as Cramer calls it "biggest market of all time

Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.